Huhtala M L
Hoppe Seylers Z Physiol Chem. 1984 Jul;365(7):819-25. doi: 10.1515/bchm2.1984.365.2.819.
We have recently described the purification and characterization of a tumor-associated trypsin inhibitor (TATI). Studies on its N-terminal sequence suggested identity with the pancreatic secretory trypsin inhibitor (PSTI) (Huhtala, M.-L., Pesonen, K., Kalkkinen, N. & Stenman, U.-H. (1982) J. Biol. Chem. 257, 13713-13716). I report here the occurrence of a TATI-like activity in human seminal plasma. Concentrations of this inhibitor in seminal plasma varied considerably (4-500 ng/ml, n = 50). In radioimmunoassay the dose-response curves of the new seminal plasma inhibitor and purified TATI were parallel. The similarity between these two inhibitors was demonstrated by gel filtration, reverse phase liquid chromatography and ion-exchange chromatography. By ion exchange chromatography the new inhibitor could be separated from the main seminal plasma trypsin inhibitors. Purified TATI was shown to inhibit human acrosin effectively.
我们最近描述了一种肿瘤相关胰蛋白酶抑制剂（TATI）的纯化及特性。对其N端序列的研究表明它与胰腺分泌型胰蛋白酶抑制剂（PSTI）相同（胡塔拉，M.-L.，佩索宁，K.，卡尔基宁，N. & 斯滕曼，U.-H.（1982年）《生物化学杂志》257，13713 - 13716）。我在此报告人精浆中存在类似TATI的活性。这种抑制剂在精浆中的浓度差异很大（4 - 500纳克/毫升，n = 50）。在放射免疫分析中，新的精浆抑制剂和纯化的TATI的剂量反应曲线是平行的。通过凝胶过滤、反相液相色谱和离子交换色谱证明了这两种抑制剂之间的相似性。通过离子交换色谱，新抑制剂可与主要的精浆胰蛋白酶抑制剂分离。纯化的TATI被证明能有效抑制人顶体蛋白酶。
